CLINICAL TRIALS PROFILE FOR SOLU-CORTEF

All Clinical Trials for SOLU-CORTEF

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002798 ↗	Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 3	1996-08-01	Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia or myelodysplastic syndrome
NCT00002855 ↗	Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 3	1996-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
NCT00002855 ↗	Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer	Completed	M.D. Anderson Cancer Center	Phase 3	1996-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	Children's Cancer Group	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00003593 ↗	Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 3	1999-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase III trial to study the effectiveness of combination chemotherapy in treating children who have Down syndrome and myeloproliferative disorder, acute myelogenous leukemia, or myelodysplastic syndrome.
NCT00003593 ↗	Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome	Completed	Children's Oncology Group	Phase 3	1999-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase III trial to study the effectiveness of combination chemotherapy in treating children who have Down syndrome and myeloproliferative disorder, acute myelogenous leukemia, or myelodysplastic syndrome.

Clinical Trial Conditions for SOLU-CORTEF

Condition Name

Condition Name for SOLU-CORTEF
Intervention	Trials
Prostate Cancer	4
T-cell Childhood Acute Lymphoblastic Leukemia	3
Adrenal Insufficiency	3
Recurrent Childhood Acute Lymphoblastic Leukemia	3

Condition MeSH

Condition MeSH for SOLU-CORTEF
Intervention	Trials
Leukemia	10
Precursor Cell Lymphoblastic Leukemia-Lymphoma	7
Leukemia, Lymphoid	7
Prostatic Neoplasms	5

Clinical Trial Locations for SOLU-CORTEF

Trials by Country

Trials by Country for SOLU-CORTEF
Location	Trials
United States	366
Canada	46
Australia	13
Puerto Rico	6
New Zealand	6

Trials by US State

Trials by US State for SOLU-CORTEF
Location	Trials
California	15
Texas	12
Pennsylvania	11
Ohio	10
New York	10

Clinical Trial Progress for SOLU-CORTEF

Clinical Trial Phase

Clinical Trial Phase for SOLU-CORTEF
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	9
Phase 2	9

Clinical Trial Status

Clinical Trial Status for SOLU-CORTEF
Clinical Trial Phase	Trials
Completed	15
Recruiting	5
Active, not recruiting	4

Clinical Trial Sponsors for SOLU-CORTEF

Sponsor Name

Sponsor Name for SOLU-CORTEF
Sponsor	Trials
National Cancer Institute (NCI)	15
Children's Oncology Group	6
Diurnal Limited	4

Sponsor Type

Sponsor Type for SOLU-CORTEF
Sponsor	Trials
Other	43
NIH	18
Industry	14

Solu-Cortef (hydrocortisone sodium succinate): Clinical Trial Update, Market Analysis, and Projection

Last updated: May 1, 2026

What is Solu-Cortef and what drives its clinical pipeline today?

Solu-Cortef is the brand name for hydrocortisone sodium succinate, an injectable corticosteroid formulation. In the US market, hydrocortisone sodium succinate is established and widely available as a “legacy” sterile injectable; as a result, near-term clinical activity is dominated by label-maintenance, formulation/manufacturing work, and occasional comparative or observational studies rather than new-moA blockbuster registrational programs.

Regulatory anchor (US label / historical positioning): Hydrocortisone sodium succinate has longstanding indications across inflammatory and adrenal insufficiency contexts, with the injectable product used in acute settings where IV corticosteroid delivery is required. (Package insert and FDA labeling data are the primary references for current permitted uses.) [1]

What is the latest clinical trial activity for Solu-Cortef/hydrocortisone sodium succinate?

Public clinical-trial activity for hydrocortisone sodium succinate is typically fragmented across:

• Indications (adrenal insufficiency, severe inflammatory states, shock/ICU contexts)
• Population (pediatrics vs adult critical care; perioperative adrenal suppression contexts)
• Study design (observational cohorts, retrospective analyses, and interventional comparisons using the same active ingredient)

For market-relevant decisioning, the question is not “is hydrocortisone being studied” but whether new trials are changing the competitive landscape (new dosing regimens with label expansion, new combinations, or new delivery systems that reset demand). In practice, the public pipeline for hydrocortisone sodium succinate does not currently show a clear pattern of registrational trial waves comparable to newer biologics or kinase inhibitors.

Actionable implication: treating Solu-Cortef as a brand with a “pipeline” lens often yields more value from regulatory and supply-chain signals than from trial readouts.

What does the market look like for hydrocortisone sodium succinate / Solu-Cortef?

Market structure

The market for injectable hydrocortisone sodium succinate is shaped by:

• Generic competition and multiple manufacturers (US supply is typically competitive)
• Hospital and emergency use procurement (high volume, tender-based purchasing)
• Formulary continuity (brands persist mainly through contracting and procurement preferences, not through differentiation)

Demand drivers

Demand is supported by:

• Adrenal insufficiency management (including acute decompensation requiring IV dosing)
• Acute inflammatory and immune conditions where IV corticosteroid is standard of care
• ICU and emergency medicine utilization where IV hydrocortisone is used for specific protocols and physician-directed care

Supply and pricing dynamics

Injectable corticosteroids are sensitive to:

• Sterile manufacturing capacity
• Raw material and intermediate availability
• Global supply interruptions (which can temporarily tighten supply and move pricing)

In this category, brand-level forecasting often tracks health system purchasing behavior more closely than clinical-trial cadence.

How should investors and R&D planners project Solu-Cortef demand over the next 5 years?

Projection framework (brand-level)

Because hydrocortisone sodium succinate is mature and heavily generics-exposed, projections should be anchored on:

1. Procedure- and ICU-driven utilization trends (beds, admissions, acute care throughput)
2. Formulary penetration and substitution rates (brand vs generic mix)
3. Pricing intensity (tender dynamics; net price vs list price)
4. Supply availability and any shortages (brief spikes then normalization)
5. Regulatory label stability (maintenance keeps baseline demand stable)

Directional 5-year scenario

The category is unlikely to face demand collapse absent changes to standards of care. Growth is more likely to be modest and pricing-dependent.

Below is a practical scenario structure for US brand-level net sales of a branded hydrocortisone sodium succinate product. Ranges reflect market realities: generics substitute when price pressure intensifies; supply shocks can create short spikes.

Scenario	Assumptions	Likely brand net sales trajectory (US)
Base case	Continued generic share; stable acute-care utilization; periodic procurement price resets	Low single-digit CAGR (nominal), with volume stability and net price pressure
Upside	Favorable hospital contracts; supply constraints reduce substitution; limited competitor stock-outs	Mid single-digit CAGR for a branded product, price supports partially offset volume share erosion
Downside	Intensified tender pressure and substitution; additional competitor supply increases price competition	Flat to negative nominal CAGR; volume erosion leads to net sales decline

What would shift the curve?

The two main shifts are:

• Substitution dynamics: if branded contracts become less favorable, brand share declines even if total category use remains steady
• Clinical standard-of-care changes: if guidelines move away from IV hydrocortisone in key indications, total category demand could contract

What is the competitive position of Solu-Cortef versus alternatives?

Competitors inside the same active ingredient class

• Generic hydrocortisone sodium succinate (sterile injection) from multiple manufacturers
• Alternative IV corticosteroids used in certain protocols (e.g., dexamethasone, methylprednisolone) depending on the indication and guideline preferences

Differentiation reality

For Solu-Cortef, differentiation is usually contract-based:

• Availability and lead time
• Hospital-specific formulary preference
• Storage and administration fit
• Net unit price after rebates and procurement adjustments

This is consistent with a mature, off-patent small-molecule injectable market structure. [1]

Key clinical-readout considerations for future trial relevance

Even if trials continue, their commercial value depends on whether they:

• Change dose, timing, or selection in key labeled and off-label practices
• Support a new indication where IV hydrocortisone becomes first-line
• Improve safety or outcome enough to alter guideline inclusion

Absent those shifts, new clinical data tends to sustain rather than expand category demand.

Key takeaways

• Solu-Cortef (hydrocortisone sodium succinate) sits in a mature, generics-exposed injectable corticosteroid market where clinical trial updates rarely translate into major demand expansion.
• Near-term clinical activity is more likely to be label maintenance, observational work, and protocol studies rather than new registrational programs that reset the competitive landscape.
• Market growth is likely to be modest and driven by hospital utilization and pricing intensity rather than new clinical differentiation.
• Forecasts should focus on brand share within tender-driven procurement, supply stability, and any standards-of-care changes that alter IV steroid selection.

---

FAQs

How much does clinical trial activity impact Solu-Cortef sales?

Clinical activity typically has limited direct sales impact unless trials produce guideline-supported changes in dosing or indication selection that shift clinician behavior at scale.

Is Solu-Cortef protected by patents that materially change competition?

Solu-Cortef is generally treated as a mature small-molecule injectable where generics drive competition; brand economics depend more on contracting than on patent-led exclusivity.

What are the main demand drivers for hydrocortisone sodium succinate?

Adrenal insufficiency acute management and acute inflammatory use in emergency and ICU settings are the primary utilization anchors.

What is the biggest downside risk in projections?

Accelerated generic substitution and intensified tender price pressure, which can reduce brand net price and share even if total category utilization remains stable.

What would create upside beyond category growth?

Hospital contract wins that protect brand share, coupled with supply constraints that temporarily reduce the ease of substitution to competing products.

---

References

[1] FDA. “Solu-Cortef (hydrocortisone sodium succinate) Prescribing Information / Label.” U.S. Food and Drug Administration. (Accessed via FDA labeling databases.)